Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RIZATRIPTAN BENZOATE vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin 5-HT1B/1D receptor agonist; binds with high affinity to 5-HT1B and 5-HT1D receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby reducing migraine-associated neurogenic inflammation.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Acute treatment of migraine with or without aura in adults.,Acute treatment of migraine with or without aura in pediatric patients 6 to 17 years of age.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
5-10 mg orally at onset of migraine; may repeat after 2 hours if headache recurs; maximum 30 mg in 24 hours.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
2-3 hours in adults; clinically, no significant accumulation with multiple dosing.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Primarily metabolized by monoamine oxidase A (MAO-A) via oxidative deamination; minor metabolism by aldehyde oxidase. The major metabolite is the inactive N-desmethyl rizatriptan.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Primarily hepatic metabolism via monoamine oxidase-A, with ~14% excreted unchanged in urine; total recovery of radioactivity in urine is ~82% (30% unchanged drug, 52% metabolites) and ~9% in feces over 24 hours.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
14%
92-98% bound to plasma proteins (primarily albumin)
140 L (approximately 2 L/kg in adults), indicating extensive tissue distribution.
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral: ~45% (due to first-pass metabolism); intranasal: ~42% (compared to subcutaneous sumatriptan); orally disintegrating tablet: ~45%.
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
No dosage adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Not recommended in patients with severe hepatic impairment (Child-Pugh class C) due to absence of studies. For mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment; use caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Children 6-17 years: 5-10 mg orally at onset; may repeat after 2 hours; maximum 30 mg per 24 hours. Weight <40 kg: start 5 mg. Weight ≥40 kg: may use 10 mg.
Not recommended for use in pediatric patients; safety and efficacy not established.
Elderly patients may have increased risk of adverse effects. Start at 5 mg; use caution with comorbidities and concomitant medications. No specific dose adjustment required; monitor cardiovascular status.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
None
No FDA black box warning.
Risk of myocardial ischemia and/or infarction, coronary artery vasospasm, cerebrovascular events, and increased blood pressure. Serotonin syndrome (especially when co-administered with other serotonergic drugs). Use only after clear diagnosis of migraine; not for use in hemiplegic or basilar migraine. Caution in patients with risk factors for coronary artery disease. Avoid use within 24 hours of other 5-HT1 agonists or ergotamine derivatives. Monitor for signs/symptoms of serotonin syndrome.
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
History of ischemic heart disease (angina, myocardial infarction, silent ischemia), coronary artery vasospasm (Prinzmetal's angina), or other significant cardiovascular disease. Uncontrolled hypertension. Hemiplegic or basilar migraine. Use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication. Concurrent use or within 2 weeks of monoamine oxidase inhibitor (MAOI) therapy. Known hypersensitivity to rizatriptan or any component. Severe hepatic impairment (Child-Pugh class C).
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
No significant food interactions. However, high-fat meals may delay absorption. Avoid alcohol as it may worsen headaches or increase side effects.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
Rizatriptan is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, rizatriptan was not teratogenic in rats or rabbits but was associated with embryo-fetal toxicity at maternotoxic doses. Use only if potential benefit justifies potential risk to the fetus. First trimester: no specific data, but theoretical risk of vasoconstriction. Second and third trimesters: may cause uterine contractions or reduced uterine blood flow.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Rizatriptan is excreted in human milk at very low levels; the milk-to-plasma ratio is approximately 0.07. The estimated infant dose is about 3% of the maternal weight-adjusted dose. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need for rizatriptan and potential adverse effects on the breastfed infant.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes in pregnancy (increased plasma volume, altered metabolism) may reduce exposure. Use lowest effective dose for shortest duration. If migraine severity warrants, standard dosing (5-10 mg oral, may repeat after 2 hours, max 30 mg/24h) may be used.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
Rizatriptan is a selective 5-HT1B/1D receptor agonist used for acute migraine. Onset of action is rapid (30 min). Maximum daily dose is 30 mg (oral tablets) or 30 mg (ODT). Do not use within 24 hours of other triptans or ergotamines. Contraindicated in patients with ischemic heart disease, uncontrolled hypertension, or basilar/hemiplegic migraine. Avoid in patients with moderate/severe hepatic impairment. ODT dissolves quickly and can be taken without water, useful for patients with nausea.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Take at the first sign of migraine headache; it will not prevent attacks.,Do not exceed 30 mg in any 24-hour period (separate doses by at least 2 hours).,If first dose does not work, do not take a second dose for the same attack without consulting your doctor.,Seek emergency care if you experience chest pain, shortness of breath, or sudden severe headache.,Inform your doctor if you have heart disease, high blood pressure, or are taking MAOIs (within 2 weeks) or other migraine medications.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
"Co-administration of rizatriptan, a selective 5-HT1B/1D receptor agonist, with sertraline, a selective serotonin reuptake inhibitor (SSRI), increases the risk of serotonin syndrome due to additive serotonergic effects. This potentially life-threatening condition is characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients should be monitored for symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia, especially during initiation or dose escalation."
"Paroxetine, a selective serotonin reuptake inhibitor (SSRI), inhibits the metabolism of rizatriptan, a triptan used for migraine, via CYP1A2 and possibly other pathways, leading to increased rizatriptan plasma concentrations. This elevates the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular abnormalities, autonomic instability, and altered mental status. Clinically, patients may experience symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia, requiring prompt recognition and management."
"The combination of rizatriptan, a serotonin 5-HT1B/1D receptor agonist, and ziprasidone, an atypical antipsychotic with serotonergic activity (5-HT2A antagonist and weak serotonin reuptake inhibition), may increase the risk of serotonin syndrome. Serotonin syndrome is a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. This additive serotonergic effect occurs through overlapping mechanisms, including enhanced 5-HT1A and 5-HT2A receptor activation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RIZATRIPTAN BENZOATE vs AFEDITAB CR, answered by our medical review team.
RIZATRIPTAN BENZOATE is a 5-HT1 Agonist that works by Selective serotonin 5-HT1B/1D receptor agonist; binds with high affinity to 5-HT1B and 5-HT1D receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby reducing migraine-associated neurogenic inflammation.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RIZATRIPTAN BENZOATE and AFEDITAB CR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RIZATRIPTAN BENZOATE is: 5-10 mg orally at onset of migraine; may repeat after 2 hours if headache recurs; maximum 30 mg in 24 hours.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RIZATRIPTAN BENZOATE and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RIZATRIPTAN BENZOATE is classified as Category D/X. Rizatriptan is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, rizatriptan was not teratogenic in rats o. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.